Agios Pharmaceuticals, Inc. (LON:0HB0)

Market Cap	1.41B
Revenue (ttm)	28.66M
Net Income (ttm)	515.47M
Shares Out	n/a
EPS (ttm)	8.86
PE Ratio	2.74
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Average Volume	99
Open	33.80
Previous Close	33.08
Day's Range	33.74 - 33.80
52-Week Range	23.82 - 62.60
Beta	n/a
RSI	56.06
Earnings Date	Aug 7, 2025

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 488
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HB0

Financial Performance

Financial numbers in USD